Table 1.
Clinical trials for combination of epigenetic drugs and Top I inhibitors.
| Top I inhibitor | Epigenetic drug | Phase | Cancer type | Status | Identifier no. |
|---|---|---|---|---|---|
| Topotecan | Hydralazine, Magnesium valproate | II | Cervical, Breast, Lung, testicular, Ovarian | Completed | NCT00404508 |
| Topotecan | Vorinostat | I/II | Small cell lung | Terminated (insufficient enrollment) | NCT00697476 |
| Topotecan | Tazemetostat | I | Small cell lung | Recruiting | NCT05353439 |
| Karenitecin | Valproic acid | I/II | Melanoma | Terminated | NCT00358319 |
| Irinotecan | Guadecitabine | I/II | Colorectal | Completed | NCT01896856 |
| Irinotecan | CPI-0209 | I/II | Urothelial, Ovarian, Endometrial, Lymphoma, Mesothelioma, Prostate | Recruiting ‘primary outcome changed’ | NCT04104776 |
| Irinotecan | DS-3201b | I/II | Small cell lung | Recruiting | NCT03879798 |